Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, and Dr. Marjorie Green, senior vice president and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck KGaA’sMRK-1.94%decrease; red down pointing triangle shares jumped after the German company said booming artificial-intelligence demand would help its electronics sales grow faster than ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Merck & Company ( (MRK) ) has released its Q3 earnings. Here is a breakdown of the information Merck & Company presented to its ...

Merck boasts more than six blockbuster drugs in its portfolio, with blockbuster PD-L1 inhibitor Keytruda being the key ...

For More Such Health News, visit rttnews.com. Merck NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

With an expanded usage recommendation from the CDC's Advisory Committee on Immunization Practices (ACIP), pneumococcal conjugate vaccines from Pfizer and Merck ... of Health and Human Services ...